COMMUNIQUÉS West-GlobeNewswire
-
Ally Medical ER Is Coming to Magnolia
09/06/2026 -
Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.
09/06/2026 -
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
09/06/2026 -
Koi Peptides Survey Finds 75% of Lab Researchers Cite Sourcing Quality as Top Concern
09/06/2026 -
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
09/06/2026 -
BPGbio Appoints Renowned Neuroscientist Eric J. Nestler, M.D., Ph.D., as Chair of Scientific Advisory Board
09/06/2026 -
Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022
09/06/2026 -
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
09/06/2026 -
Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long-Acting Anti-TSLP Antibody WIN378
09/06/2026 -
Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery
09/06/2026 -
ENvue Medical Launches AI Training Platform Establishing Artificial Intelligence Foundation for Robotic Feeding Tube Navigation
09/06/2026 -
Kraig Biocraft Laboratories Sets New All-Time Production Record, Delivering Nearly 2.5 Metric Tons of Recombinant Spider Silk in Single Production Cycle
09/06/2026 -
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria
09/06/2026 -
Flyte Announces World Cup Activation Strategy, Targeting Global Travel Demand Surrounding 2026 Tournament
09/06/2026 -
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
09/06/2026 -
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
09/06/2026 -
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
09/06/2026 -
Le gala Le Bal Rouge de la Fondation du CUSM recueille un montant record de 2 223 306 $ pour accélérer les découvertes en santé au site Glen du CUSM
09/06/2026 -
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
09/06/2026
Pages